Pre-market: CHM.AX stock down 20% to A$0.002 on ASX: watch catalysts ahead
CHM.AX stock plunged 20.0% pre-market to A$0.002 on the ASX after heavy selling into low liquidity. We saw 600,000 shares trade versus a 50-day average of 5,804,285, a sign that small orders can move the price. With an upcoming earnings announcement on 26 Feb 2026 and clinical trial readouts pending, traders are re-pricing risk for Chimeric Therapeutics Limited (CHM.AX) in Australia.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
